Status:
RECRUITING
The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19
Lead Sponsor:
Hellenic Institute for the Study of Sepsis
Conditions:
Pulmonary Complications
Cardiovascular Complications
Eligibility:
All Genders
18+ years
Brief Summary
More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted be...
Detailed Description
Post-acute phase of COVID and Non-communicable diseases Following the emergence of SARS-CoV-2, more than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU a...
Eligibility Criteria
Inclusion
- Group A (comparators)
- Adults (18 years or more) of both genders
- Negative history of acute COVID-19
- Group B (patients with ΝΟ dysfunction)
- Adults (18 years or more) of both genders
- History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
- Absence of any current overt organ dysfunction
- Absence of signs of any organ dysfunction during acute COVID-19
- Group C (patients with dysfunctions)
- Adults (18 years or more) of both genders
- History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
- Presence of signs of organ dysfunction of the lung, the kidneys or the heart during acute COVID-19
Exclusion
- Group A (comparators)
- Any other co-existing disorder generating clinical symptoms
- Failure to thrive according to the attending physicians
- Pregnancy or lactation
- Group B (patients with ΝΟ dysfunction)
- Any other co-existing disorder generating clinical symptoms
- Failure to thrive according to the attending physicians
- Pregnancy or lactation
- Group C (patients with dysfunctions)
- Any other co-existing disorder generating clinical symptoms
- Medical history of any of:
- stage III or IV chronic obstructive pulmonary disease according to the GOLD criteria
- pulmonary fibrosis or pulmonary hypertension
- stage IV solid tumour malignancy under chemotherapy or radiotherapy
- systemic sclerosis
- congestive heart failure
- stage II, III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
- Limited chance of survival for at least six months due to co-existing comorbidity(-ies) according to the judgement of the attending physicians
- Pregnancy or lactation
Key Trial Info
Start Date :
December 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 4 2027
Estimated Enrollment :
345 Patients enrolled
Trial Details
Trial ID
NCT06608849
Start Date
December 10 2024
End Date
November 4 2027
Last Update
November 17 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases
Athens, Greece
2
4th Department of Internal Medicine, ATTIKON University General Hospital
Athens, Greece
3
Obstructive Diseases Clinic, Sotiria Athens Hospital of Chest Diseases
Athens, Greece
4
Out-patient department of Infectious Diseases, Sotiria Athens Hospital of Chest Diseases
Athens, Greece